Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.46
- Piotroski Score 3.00
- Grade Overweight
- Symbol (AXSM)
- Company Axsome Therapeutics, Inc.
- Price $89.78
- Changes Percentage (0.16%)
- Change $0.14
- Day Low $88.89
- Day High $90.36
- Year High $98.40
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/03/2024
- Fiscal Year End N/A
- Average Stock Price Target $111.50
- High Stock Price Target $180.00
- Low Stock Price Target $80.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$6.45
- Trailing P/E Ratio -11.46
- Forward P/E Ratio -11.46
- P/E Growth -11.46
- Net Income $-239,238,000
Income Statement
Quarterly
Annual
Latest News of AXSM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Jim Cramer Thinks Axsome Therapeutics Inc (NASDAQ:AXSM) Stock Can Double
Insider Monkey recently highlighted Jim Cramer's top 10 stock picks, with Axsome Therapeutics Inc ranking 4th. Cramer discussed the impact of China on US stocks, noting challenges faced by companies w...
By Yahoo! Finance | 1 month ago -
Axsome Therapeutics (AXSM) Q2 2024 Earnings Call Transcript
During the Axsome Therapeutics Q2 2024 financial results conference call, they highlighted strong commercial performance and pipeline advancements. Key upcoming milestones include results from phase 3...
By Yahoo! Finance | 1 month ago -
Investors ignore increasing losses at Axsome Therapeutics (NASDAQ:AXSM) as stock jumps 7.0% this past week
Investing in stocks carries risks of potential loss, but also opportunities for significant gains. Axsome Therapeutics Inc. (NASDAQ: AXSM) has shown impressive growth, with a 217% increase in share pr...
By Yahoo! Finance | 3 months ago
